Lava Therapeutics Company
Lava Therapeutics is a developer of a bispecific antibody platform used to engage gamma-delta T cells for the treatment of cancer.
Industry:
Atrificial Vectors and Immune Cells
Last Funding Type:
Series C
Funding Status:
IPO
Estimated Revenue:
$1M to $10M
Total Funding:
102854807
Investors Number:
9
Headquarters:
Utrecht, Utrecht, The Netherlands
Last Funding Date:
2020-09-17
Founded Date:
2016-01-01
Employee Number:
51-100